Benitec Limited Company Profile

12:34 EST 16th December 2018 | BioPortfolio

Benitec Ltd. is a leading international biotechnology company listed on the Australian Stock Exchange. Benitec was founded in 1997 to commercialize research from Queensland's Department of Primary Industries (DPI).

Benitec is one of the pioneers of RNA interference (RNAi) technology, which can be used to precisely destroy RNA viruses and silence the expression of defective genes. Benitec’s core patents provide key technologies to trigger RNAi in human cells and in live animals and are jointly owned with Australia’s Commonwealth Scientific and Industrial Research Organization (CSIRO). Benitec holds exclusive worldwide rights for development and commercialization for all human applications.

The corporate goal of Benitec is to develop RNA interference (RNAi)-based therapeutics for serious diseases such as Hepatitis C Viral infection and AIDS caused by the Human Immunodeficiency Virus (HIV). Benitec’s RNA-based HIV therapeutic, co-developed with the City of Hope in Duarte, California, will enter Phase I clinical trials in 2006.


C/- Adsto InternationalAdsto House
401 New Canterbury Road
P.O. Box 20
Dulwich Hill
New South Wales
NSW 2203


Phone: 61 2 9560 1110
Fax: 61 2 9388 7313

News Articles [57 Associated News Articles listed on BioPortfolio]

How Benitec’s ddRNAi technology can overcome the challenges of siRNA-based methods.

Georgina Kilfoil, Chief Clinical Officer of Benitec Biopharma, discusses Benitec’s unique gene-silencing technology.

How close are Benitec to a 'one dose' cure using ddRNAi therapeutics?

In February 2014, Benitec secured AUD31.5 million in funding from quality US healthcare institutional investors This funding enables Benitec to advance TT034 to the conclusion of phase II(b) clinical ...

Axovant licenses worldwide rights to Benitec's BB301 and five other CNS gene therapy programs

Axovant Sciences Ltd. licensed exclusive worldwide rights to Benitec Biopharma Ltd.'s preclinical oculopharyngeal muscular dystrophy (OPMD) candidate BB301, which Axovant has renamed AXO-AAV-OPMD. The...

Axovant and Benitec estbalish gene therapy partnership

Pharmaceutical company Axovant Sciences has signed a gene therapy licensing and development deal with Australia-based Benitec Biopharma to expand its...Read More... The post Axovant and Benitec estbal...

Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders

Axovant Sciences has licensed exclusive rights to Benitec Biopharma’s preclinical gene therap y for oculopharyngeal muscular dystrophy (OPMD), set to enter the clinic next year, and five additional ...

Benitec: Peter French explains the potential of their gene silencing technology in lung cancer, hepatitis Band neuropathic pain.

In this episode of PharmaTelevision News Review, Fintatn Walton talks to Peter French, CEO of Benitec

Axovant, Benitec sign licensing deal for AXO-AAV-OPMD program

Axovant Sciences has entered into a global licensing agreement with Benitec Biopharma for BB-301 (AXO-AAV-OPMD) platform to treat oculopharyngeal muscular dystrophy (OPMD).

Axovant Significantly Expands Pipeline with Licensing Deal with Benitec BioPharma

Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian compan...

PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [86 Associated Companies listed on BioPortfolio]

Benitec Ltd

Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - som...

Benitec Limited

Benitec Ltd. is a leading international biotechnology company listed on the Australian Stock Exchange. Benitec was founded in 1997 to commercialize research from Queensland's Department of Primary Ind...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...


More Information about "Benitec Limited" on BioPortfolio

We have published hundreds of Benitec Limited news stories on BioPortfolio along with dozens of Benitec Limited Clinical Trials and PubMed Articles about Benitec Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Benitec Limited Companies in our database. You can also find out about relevant Benitec Limited Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Corporate Database Quicklinks

Searches Linking to this Company Record